Saffron has been studied as a supplement for age-related macular degeneration (AMD), but no trial shows that eating saffron or drinking saffron tea prevents blindness. Small and medium-sized studies have reported changes in certain retinal-function measures. That is promising research, not a replacement for an eye examination, proven AMD care, or UV-blocking sunglasses.
The old phrase “increase the visual quality in saffron Ghaenat” is better understood as a question: can saffron from Ghaenat improve vision? The evidence concerns specific standardised supplements in diagnosed patients, not a special therapeutic effect established for saffron from one growing region.
What age-related macular degeneration affects
AMD damages the macula, the central part of the retina used for reading, recognising faces, and seeing fine detail. It can blur or distort the centre of vision while side vision remains. Dry and wet AMD behave differently and may require different monitoring or treatment.
“Low vision” is not one disease. Cataract, glaucoma, diabetic eye disease, retinal detachment, medication effects, and many other conditions can change sight. A spice cannot be recommended until the cause is known.
What the first three-month saffron trial found
The widely repeated story traces largely to a 2010 Italian crossover trial, not to proof that saffron prevented blindness. Twenty-five people with early AMD received either 20 mg per day of oral saffron or placebo for three months, then crossed to the other treatment for a further three months.
The study measured focal electroretinogram responses, including retinal flicker sensitivity. Those measures improved during saffron supplementation compared with placebo. In their published report, the researchers said the result needed replication and that its clinical significance still had to be evaluated.
The trial did not show that saffron stopped anyone becoming blind. It did not test saffron tea, a Mediterranean diet, or ordinary culinary servings. Its 20 mg capsule was a controlled intervention used in patients already diagnosed with early AMD.
Correcting the University of Sydney and Professor Bisti story
The source articles combined details from different research programmes. Silvia Bisti—often misspelled “Sylvia Beasti”—was a co-author of the 2010 Italian trial. The paper’s clinical team was based in Italy, and Benedetto Falsini was its first author. It should not be described as a University of Sydney trial led by Professor Bisti.
Australian researchers later ran a separate double-blind crossover trial in 100 people with mild or moderate AMD. Participants received 20 mg saffron or placebo for three months and then crossed over. That study was registered in Australia and New Zealand and involved a Sydney retinal clinic.
A subsequent open-label extension followed 93 adults taking 20 mg daily for 12 months. The 2024 report found improvements in some multifocal electroretinogram response-density measures, no significant latency change, and an average best-corrected visual acuity that was 1.6 letters worse. The authors reported no saffron-related serious adverse events, but an open-label extension without a concurrent placebo group cannot prove prevention.
Why “natural spectacles” is misleading
The source called saffron “natural spectacles” or “natural goggles” that protect the eyes from strong sunlight. That is a media-friendly metaphor, not a clinical endpoint. Swallowing saffron does not physically block ultraviolet radiation, and the AMD trials did not establish it as sun protection.
For actual UV protection, the U.S. National Eye Institute recommends sunglasses labelled for 99–100% UVA and UVB protection or UV400, a good fit that limits light around the lenses, and a broad-brimmed hat. Saffron is not a substitute for any of them.
Does saffron prevent blindness?
No. “Blindness” covers many causes, and the saffron studies concern selected retinal conditions in relatively small groups. An improvement in an electrical retinal response is not the same as preventing blindness, restoring lost sight, or treating every eye disease.
A 2021 systematic review of saffron and ocular disorders found only nine clinical studies among 29 relevant papers and concluded that further clinical research was needed. Laboratory findings involving retinal cells and animals can help form hypotheses, but they do not establish a treatment for a person.
How crocin and other compounds fit the evidence
Crocin and crocetin are saffron carotenoids studied for antioxidant and retinal effects. Their presence provides a plausible research direction, but naming a compound does not prove that culinary saffron regenerates eye nerves.
Picrocrocin is associated mainly with saffron’s bitter taste. The old destination treated high picrocrocin as if it demonstrated an effect on low vision; human trials do not support that shortcut. Safranal contributes importantly to aroma and has separate laboratory literature, but it is not an approved blindness treatment.
What supplement evidence is established for AMD
The best-established nutritional supplement approach is the AREDS2 formula for particular stages of AMD—not for everyone and not as a cure. The National Eye Institute’s AMD guidance says AREDS2 can help slow progression in people with intermediate AMD in one or both eyes and may help when late AMD is present in one eye.
AREDS2 cannot prevent early AMD from becoming intermediate AMD, and it is not the right formula for every person. Its doses are much higher than ordinary food or a multivitamin and may interact with medicines. An eye doctor should determine the AMD stage and whether AREDS2, treatment for wet AMD, monitoring, or low-vision support applies.
Culinary saffron is not a trial capsule
A capsule containing 20 or 30 mg of a specified saffron preparation is not equivalent to “some saffron” in tea, rice, or dessert. Recipes vary in thread weight, grade, storage, extraction, serving size, and number of people sharing the dish.
The trial quantities in this article describe research; they are not a recommendation to self-treat. Anyone considering a concentrated saffron supplement should show the product and full ingredient list to an eye doctor, physician, or pharmacist, particularly when pregnant, preparing for surgery, managing low blood pressure, or taking prescription medicine.
What you can do to protect vision
- Have regular dilated eye examinations at the interval recommended for your age, family history, diabetes status, and existing eye findings.
- Wear sunglasses that block 99–100% of UVA and UVB radiation or carry a UV400 label, and add a brimmed hat outdoors.
- Do not smoke; stopping lowers risk for several eye diseases and improves health beyond vision.
- Manage diabetes and high blood pressure with the clinicians treating them.
- Eat a varied diet that includes dark leafy vegetables and other nutrient-rich foods rather than relying on one spice.
- Use prescribed eye medication and anti-VEGF or other treatment exactly as directed; saffron does not replace it.
These steps reflect the National Eye Institute’s practical vision guidance. They protect against more than one narrow study outcome.
When a vision change needs urgent assessment
New distortion, a dark or blank central area, a curtain or shadow over vision, flashes with a sudden shower of floaters, eye injury, severe eye pain, or sudden partial or complete vision loss should not wait for a supplement experiment. Contact an urgent eye-care or emergency service promptly.
Gradual blur, difficulty reading, reduced contrast, or trouble recognising faces also deserves an eye examination. Earlier diagnosis can preserve treatment options.
Does Ghaenat origin change the eye evidence?
Ghaenat, or Qaenat, is an important saffron-growing area in South Khorasan, Iran. Origin matters for traceability, agricultural tradition, sensory quality, and trade. It does not establish that one region’s saffron improves visual function more than another’s.
Clinical evidence belongs to the exact material tested. A retail product needs its own identity, purity, dose, and quality information before a trial result can even be discussed sensibly. Regional reputation alone is not pharmaceutical standardisation.
The careful conclusion on saffron and eyesight
Saffron research in AMD is worth following. The early Italian trial and later Australian programme reported changes in retinal-function measures, but neither justifies the promise “prevent blindness by consuming saffron.” The most recent long-term report did not show improved best-corrected visual acuity.
Enjoy genuine Ghaenat saffron as food from our saffron collection if you like its aroma and colour. Treat eye symptoms, AMD supplements, and concentrated saffron capsules as medical questions for an eye-care professional—not as conclusions from a company blog.
